source
- Epilepsy drug from Ovid and Takeda receives fresh start under Perceptive-backed ventureAfter about 26 months since two Phase 3 trials failed, the epilepsy treatment candidate originally developed by Ovid Therapeutics and Takeda has been removed from their pipelines. Investment firm…
- Experts warn of deaths linked to Neurocrine's Vykat XR for Prader-Willi syndromeA coalition of specialists in Prader-Willi syndrome has raised serious concerns about the safety profile of Neurocrine Biosciences' drug Vykat XR. The experts point to a series of adverse events,…